Literature DB >> 769940

Impairment of rosette-forming T lymphocytes in patients with primary intracranial tumors.

W H Brooks, T L Roszman, A S Rogers.   

Abstract

The percentage of T lymphocytes that form rosettes (RFC) with sheep erythrocytes (E rosettes), cutaneous delayed-type hypersensitivity, and in vitro lymphocyte transformation was measured in 15 patients with primary intracranial tumors. The ability of T lymphocytes to form E rosettes was significantly impaired. These patients also exhibited impaired ability to become sensitized to dinitrochlorobenzene and humoral suppression of PHA-induced lymphocyte blastogenesis. The hypothetical role of antibody(s) to possible shared antigenic determinants on brain and T cells is discussed.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 769940     DOI: 10.1002/1097-0142(197604)37:4<1869::aid-cncr2820370435>3.0.co;2-q

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  31 in total

1.  The mononuclear cell infiltrate compared with survival in high-grade astrocytomas.

Authors:  M L Rossi; N R Jones; E Candy; J A Nicoll; J S Compton; J T Hughes; M M Esiri; T H Moss; F F Cruz-Sanchez; H B Coakham
Journal:  Acta Neuropathol       Date:  1989       Impact factor: 17.088

Review 2.  The evolution of the EGFRvIII (rindopepimut) immunotherapy for glioblastoma multiforme patients.

Authors:  Michelle Paff; Daniela Alexandru-Abrams; Frank P K Hsu; Daniela A Bota
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 3.  Neural and Pavlovian influences on immunity.

Authors:  R W Brittain; N I Wiener
Journal:  Pavlov J Biol Sci       Date:  1985 Oct-Dec

4.  T- and B-lymphocyte subpopulations in pre-invasive and invasive carcinoma of the cervix.

Authors:  R J Rand; D M Jenkins; R Bulmer
Journal:  Clin Exp Immunol       Date:  1977-12       Impact factor: 4.330

Review 5.  Current state and future prospects of immunotherapy for glioma.

Authors:  Neha Kamran; Mahmoud S Alghamri; Felipe J Nunez; Diana Shah; Antonela S Asad; Marianela Candolfi; David Altshuler; Pedro R Lowenstein; Maria G Castro
Journal:  Immunotherapy       Date:  2018-02-01       Impact factor: 4.196

Review 6.  T-cell Dysfunction in Glioblastoma: Applying a New Framework.

Authors:  Karolina I Woroniecka; Kristen E Rhodin; Pakawat Chongsathidkiet; Kristin A Keith; Peter E Fecci
Journal:  Clin Cancer Res       Date:  2018-03-28       Impact factor: 12.531

7.  Lymphocyte subsets in patients with brain tumors.

Authors:  M Uegaki; S Kobayashi; S Kuramoto; M M Yokoyama
Journal:  J Neurooncol       Date:  1988       Impact factor: 4.130

8.  Immunologic status in children with brain tumors and the effect of therapy.

Authors:  R Kebudi; I Ayan; E Darendeliler; L Ağaoğlu; S Ekmekçioğlu; T Yağci; S Pişkin; N Bilge
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

9.  Particular features of cell-mediated immunity in patients with anaplastic gliomas. A comparison with kidney and bladder cancer patients.

Authors:  F Servadei; R Parente; M Bucci; E Beltrandi; F Tognetti; G Gaist
Journal:  J Neurooncol       Date:  1983       Impact factor: 4.130

10.  Inability of mitogen-activated lymphocytes obtained from patients with malignant primary intracranial tumors to express high affinity interleukin 2 receptors.

Authors:  L H Elliott; W H Brooks; T L Roszman
Journal:  J Clin Invest       Date:  1990-07       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.